Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact
-
Jungbluth, Stefan (European Vaccine Initiative)
;
Martin, William (European Vaccine Initiative) ;
Slezak, Monika (European Vaccine Initiative) ;
Depraetere, Hilde (European Vaccine Initiative) ;
Guzman, Carlos A. (Helmholtz Centre for Infection Research) ;
Ussi, Anton (EATRIS- European Research Infrastructure for Translational Medicine) ;
Morrow, David (EATRIS- European Research Infrastructure for Translational Medicine) ;
Van Heuverswyn, Fran (Flanders Vaccine) ;
Arnouts, Sven (Ghent University) ;
Carrondo, Manuel J. T. (Instituto de Biologia Experimental e Tecnológica) ;
Olesen, Ole (European Vaccine Initiative) ;
Ottenhoff, Tom H.M. (Leiden University Medical Center) ;
Dockrell, H. M. (London School of Hygiene & Tropical Medicine) ;
Ho, Mei Mei (Medicines and Healthcare products Regulatory Agency) ;
Dobly, Alexandre (Sciensano) ;
Christensen, Dennis (Statens Serum Institut) ;
Segalés Coma, Joaquim (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal) ;
Laurent, Fabrice (Université François Rabelais de Tours) ;
Lantier, Frédéric (Université François Rabelais de Tours) ;
Stockhofe-Zurwieden, Norbert (Wageningen Bioveterinary Research) ;
Morelli, Francesca (CIRMMP) ;
Langermans, Jan A.M. (Biomedical Primate Research Centre) ;
Verreck, Frank A.W. (Biomedical Primate Research Centre) ;
Le Grand, Roger (Université Paris-Saclay) ;
Sloots, Arjen (Intravacc) ;
Medaglini, Donata (University of Siena) ;
Lawrenz, Maria (Vaccine Formulation Institute) ;
Collin, Nicolas (Vaccine Formulation Institute)
guest ::
Subscribe to this discussion. You will then receive all new comments by email.
